MedTrace Logo

Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)

NCT03983018 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-03-21

Study results available
· View outcomes & findings →

Summary

This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant schizophrenia spectrum disorder in an open trial.

Conditions

  • Schizophrenia Spectrum and Other Psychotic Disorders
  • Treatment-resistant Schizophrenia

Interventions

DRUG

Rituximab

Infusion

Sponsors & Collaborators

  • Örebro University, Sweden

    collaborator OTHER

  • Region Örebro County

    lead OTHER

Principal Investigators

  • Susanne Bejerot · Region Orebro lan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-07
Primary Completion
2022-03-31
Completion
2022-03-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03983018 on ClinicalTrials.gov